Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 4/20 | 0.38 |
| ▸ | LCK | P06239 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | NNMT | P40261 | 3/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28692305 | 0.98 | RIPK2 (0.37) | RIPK2LCKKDRTGFBR1NNMT | |
| SCHEMBL30515902 | 0.90 | NNMT (0.36) | RIPK2NNMTCDK9KDM4EGAA | |
| SCHEMBL9869341 | 0.85 | POLB (0.38) | RIPK2LCKKDRTGFBR1CDK9 | |
| SCHEMBL18395054 | 0.77 | LMNA (0.48) | KDM4ETSHRPLATNPC1 | |
| SCHEMBL13732364 | 0.77 | LMNA (0.34) | CDK9CCNT1 | |
| Carbamic Acid SCHEMBL4197078 | 0.77 | CCNT1 (0.30) | CDK9CCNT1 | |
| SCHEMBL31739404 | 0.75 | RPS6KB1 (0.40) | RIPK2NNMTCHRNB2CHRNA4CDK9 | |
| SCHEMBL5150230 | 0.75 | RIPK2 (0.33) | RIPK2LCKKDRTGFBR1CDK9 | |
| SCHEMBL1800727 | 0.74 | CCNT1 (0.30) | CDK9CCNT1 | |
| SCHEMBL10554651 | 0.74 | MAPT (0.42) | KDM4EGAARECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701357-B2 | Treatment of B cell cancers using a combination comprising Btk inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2023-07-18 | — | — | US | claimed |
| US-12202832-B2 | Heterocyclic compounds having a calcium-sensing receptor antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240409546-A1 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-12-12 | — | — | US | disclosed |
| CN-114174299-B | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligand and methods of use | 百济神州有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-114174299-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-2699577-A1 | TETRAHYDROPYRAZOLO [1,5 -A]PYRIMIDINE AS ANTI -TUBERCULOSIS COMPOUNDS | Glaxo Group Limited (GB) | 2014-02-26 | — | — | EP | disclosed |
| US-20140038989-A1 | TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| WO-2012143522-A1 | TETRAHYDROPYRAZOLO [1,5 -A] PYRIMIDINE AS ANTI -TUBERCULOSIS COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-10-26 | — | — | WO | disclosed |
| US-5013737-A | Hypotensive, anxiolytic, cognitive disorders | AMERICAN CYANAMID COMPANY (US) | 1991-05-07 | — | — | US | disclosed |
| US-4847256-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0264773-A1 | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038989-A1 | TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS | TBL3, NDUFV3, NME2 | RIPK2 3699/4885LCK 3985/4885KDR 4575/4885 |
| US-20240409546-A1 | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF | BTK, LCK, SYK | RIPK2 851/4885LCK 2/4885KDR 767/4885 |
| US-11701357-B2 | Treatment of B cell cancers using a combination comprising Btk inhibitors | BTK, LCK, SYK | RIPK2 1079/4885LCK 2/4885KDR 1179/4885 |
| US-12202832-B2 | Heterocyclic compounds having a calcium-sensing receptor antagonistic activity | CASR, RYR1, AGTR2 | RIPK2 1470/4885LCK 3319/4885KDR 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.